Gregory P. Dubé, Ph.D.

Gregory P. Dubé, Ph.D. has over 20 years of experience in research and development in the pharmaceutical industry. Gregory began their career in 1996 as a Co-Founder and Scientific Liaison at the Vancouver Vascular Biology Research Centre. In 2000, they joined Eli Lilly and Company as a Principal Research Scientist, where they championed projects to identify novel, selective new chemical entities to treat unmet medical needs in atherosclerosis, inflammation, diabetes and heart failure. In 2004, they moved to Nitromed, Inc. as the Director of Preclinical Research, where they supervised research teams in the selection, development, validation and implementation of multiple, cost-effective pharmacokinetic and pharmacodynamic animal models. In 2006, they joined Biopure Corporation as Director of Cardiovascular Research, where they developed intracoronary administration of hemoglobin-based oxygen carrier in preclinical animal models and validated efficacy in man in collaboration with a clinical trial site in Europe. In 2009, they took on roles as a Senior Director of Pharmacology at OPK Biotech, LLC and a Consultant, Research & Development at Clarimedix, Inc. In 2013, they joined Thermalin Diabetes, LLC as Senior Director, Preclinical and Clinical Programs. In 2016, they became a Consultant, Preclinical and Clinical Research at Hemoglobin Oxygen Therapeutics, LLC and Vice President, Research and Development at HbO2 Therapeutics.

Gregory P. Dubé, Ph.D. has a long and impressive educational history. Gregory obtained their B.S. in Biology from Northeastern University in 1977, followed by a Ph.D. in Pharmacology & Cell Biophysics from the University of Cincinnati College of Medicine in 1984. Gregory then completed a Postdoctoral Fellowship in Cardiology at Duke University School of Medicine in 1987. In 2002, they obtained a Consulting Pairs Moderator certification from Pope & Associates, Inc.